

ASTRAZENECA PHARMA INDIA LIMITED
Regd. Office 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024


**FINANCIAL RESULTS FOR THE
QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2011**

Sl No.	Particulars	Rs in lakhs (except for number of shares)				
		3 months ended 30.09.2011 (Unaudited)	3 months ended 30.09.2010 (Unaudited)	Year to date figure for 6 months ended 30.09.2011 (Unaudited)	Year to date figure for 9 months ended 30.09.2010 (Unaudited)	Previous accounting year (15 months period) ended 31.03.2011 (Audited)
1	(a) Net sales (net of excise duty)	14,201.37	12,436.68	27,143.19	32,260.69	57,436.20
	(b) Other operating incomes: - Service income	661.06	163.87	1,467.47	1,221.84	1,966.30
2	Expenditure					
	(a) (Increase)/ decrease in stock-in-trade and work-in-progress	(93.05)	418.36	(1,484.67)	(421.01)	(1,358.95)
	(b) Consumption of raw materials and packing materials	1,993.81	1,526.58	4,392.90	4,361.33	7,604.40
	(c) Purchase of traded goods	2,620.13	1,965.99	5,768.57	6,087.17	11,681.17
	(d) Employees cost	3,523.44	2,965.36	6,877.06	8,677.96	15,049.76
	(e) Depreciation	191.28	186.88	364.02	520.28	881.28
	(f) Other expenditure	3,639.80	3,024.62	7,367.26	10,396.73	16,074.49
	(g) Total	11,875.41	10,087.99	23,285.14	29,622.46	49,932.15
3	Profit from operations before other income, interest & exceptional items (1-2)	2,987.02	2,512.56	5,325.52	3,860.07	9,470.33
4	Other income	145.39	89.71	295.66	255.03	628.14
5	Profit before interest & exceptional items (3+4)	3,132.41	2,602.27	5,621.18	4,115.10	10,098.49
6	Interest	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	3,132.41	2,602.27	5,621.18	4,115.10	10,098.49
8	Exceptional items	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	3,132.41	2,602.27	5,621.18	4,115.10	10,098.49
10	Tax expense	1,024.01	840.70	1,837.96	1,369.68	3,685.52
11	Net profit from ordinary activities after tax (9-10)	2,108.40	1,752.57	3,783.22	2,745.42	6,412.97
12	Extraordinary item	-	-	-	-	-
13	Net profit for the period (11-12)	2,108.40	1,752.57	3,783.22	2,745.42	6,412.97
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	300.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year	-	-	-	-	17,468.96
16	Basic and diluted earnings (Rs) per share (not annualised)	8.43	7.01	15.13	10.98	25.65
17	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters and promoter group shareholding					
	a) Pledged/Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 10 November 2011.
- Status of investor complaints: a) Pending as on 1 July 2011 - NIL; b) Received during the quarter - 4; c) Disposed off during the quarter - 4; d) Pending as on 30 September 2011 - NIL.
- The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 30 September 2011 are for a 6 months period, while the corresponding figures are for a 9 months period and hence not strictly comparable.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. 'Others' comprise service income pertaining to clinical trials and co-promotion activities.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Anandh Balasundaram
Managing Director

Mumbai
Date: November 10, 2011

ASTRAZENECA PHARMA INDIA LIMITED
 Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl No.	Particulars	3 months ended 30.9.2011 (Unaudited)	3 months ended 30.9.2010 (Unaudited)	Year to date figure for 6 months ended 30.09.2011 (Unaudited)	Year to date figure for 9 months ended 30.09.2010 (Unaudited)	Previous accounting year (15 months period) ended 31.03.2011 (Audited)
1	Segment revenue					
	(a) Healthcare	14,205.80	12,442.65	27,153.66	32,277.27	57,464.43
	(b) Others	661.06	163.87	1,467.47	1,221.84	1,966.30
	Total	14,866.86	12,606.52	28,621.13	33,499.11	59,430.73
	Less: Inter-segment Revenue					
	Net income from operations	14,866.86	12,606.52	28,621.13	33,499.11	59,430.73
2	Segment results					
	Profit before tax and interest					
	(a) Healthcare	2,923.52	2,419.95	5,240.58	3,769.48	9,386.50
	(b) Others	67.93	98.58	95.41	107.17	112.08
	Total	2,991.45	2,518.53	5,335.99	3,876.65	9,498.58
	Add: Other income	140.96	83.74	285.19	238.45	599.91
	Less: Interest					
	Total profit before tax	3,132.41	2,602.27	5,621.18	4,115.10	10,098.49
3	Capital employed					
	(a) Healthcare	14,973.36	8,685.63	14,973.36	8,685.63	12,122.33
	(b) Others	463.97	280.73	463.97	280.73	644.20
	(c) Unallocated	6,314.85	8,240.55	6,314.85	8,240.55	5,202.43
	Total	21,752.18	17,206.91	21,752.18	17,206.91	17,968.96

Notes :

1 Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

2 The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April- March". The financial accounts and annual report for the year ending 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 30 September 2011 are for a 6 months period, while the corresponding figures are for a 9 months period and hence not strictly comparable.

Swamy

ASTRAZENECA PHARMA INDIA LIMITED
 Regd Office : "Avisikar" Off Bellary Road , Hebbal Bangalore - 560 024
 Disclosure of Balance Sheet Items as per clause 41(V) (b) of listing Agreement

(Rs. in lakhs)

Particulars	As at 30.09.2011 (Unaudited)	As at 30.09.2010 (Unaudited)
SHAREHOLDERS' FUNDS		
(a) Capital	500.00	500.00
(b) Reserves and Surplus	21,252.18	16,706.91
LOAN FUNDS	-	-
TOTAL	21,752.18	17,206.91
FIXED ASSETS	7,350.64	3,878.10
INVESTMENTS	0.57	0.57
DEFERRED TAX ASSETS	596.23	608.38
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	8,532.19	4,318.22
(b) Sundry Debtors	5,386.68	5,418.42
(c) Cash and Bank Balances	6,269.16	8,512.17
(d) Other Current Assets	911.52	599.07
(e) Loans and Advances	5,669.13	3,158.87
Less : Current Liabilities And Provision		
(a) Liabilities	11,119.40	7,662.43
(b) Provisions	1,844.54	1,624.46
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	-	-
PROFIT AND LOSS ACCOUNT	-	-
TOTAL	21,752.18	17,206.91

Dant